Bavarian Nordic A/S

BAVA

DK0015998017

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:52:50 2024-06-03 am EDT			5-day change	1st Jan Change
185.3 ^DKK	+0.26%		+3.43%	+4.48%

May. 31	Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	MT
May. 30	Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	MT

Bavarian Nordic A/S Announces Resignation of Elizabeth McKee Anderson from the Board

August 23, 2022 at 10:02 am EDT

Bavarian Nordic A/S announced that Elizabeth McKee Anderson has decided to step down from the board with immediate effect as she will accept a position with another company that may in the future conflict with her board position with Bavarian Nordic. Ms. Anderson has served as member of the Board since 2017 and has chaired the Science, Technology and Investment Committee.

Latest news about Bavarian Nordic A/S

Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	May. 31	MT
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	May. 30	MT
Bavarian Nordic A/S and Coalition for Epidemic Preparedness Innovations Partners to Advance Mpox Vaccination in Africa	May. 30	CI
Bavarian Nordic’s Medical Chief to Step Down by May-end	May. 21	MT
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer	May. 21	CI
Transcript : Bavarian Nordic A/S, Q1 2024 Earnings Call, May 08, 2024	May. 08
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.	May. 08	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	May. 08	CI
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	Apr. 30	MT
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	Apr. 29	CI
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	Apr. 29	MT
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	Apr. 29	CI
Bavarian Nordic A/S's Equity Buyback announced on May 9, 2023, has expired.	Apr. 15	CI
Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	Mar. 13	MT
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	Mar. 13	CI
Nordic Shares Moved Upward Wednesday; BoneSupport Holding Topped Leaders	Mar. 06	DJ
Transcript : Bavarian Nordic A/S, 2023 Earnings Call, Mar 06, 2024	Mar. 06
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Bavarian Nordic A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Nordic stocks fell Tuesday, with the OMX Nordic 40 Index declining 0.2%.	Feb. 27	DJ
Transcript : Bavarian Nordic A/S - Analyst/Investor Day	Feb. 26
Bavarian Nordic Receives Accelerated Assessment Status for Chikungunya Vaccine	Feb. 23	MT
Bavarian Nordic A/S Announces Accelerated Assessment for the Upcoming Marketing Authorisation Application for CHIKV VLP	Feb. 23	CI
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	Feb. 21	MT

Chart Bavarian Nordic A/S

Duration

Period

More charts

Company Profile

Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%). Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bavarian Nordic A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

184.8 DKK

Average target price

262 DKK

Spread / Average Target

+41.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAVARIAN NORDIC A/S	+4.51%	2.09B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+31.10%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+14.77%	240B
NOVARTIS AG	+9.26%	210B
ROCHE HOLDING AG	-5.32%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals